<DOC>
	<DOCNO>NCT02439359</DOCNO>
	<brief_summary>A Phase 1 , Placebo-Controlled , Dose-Escalating Study Examine Safety Tolerability Single Intravenous Doses CF-301 Healthy Subjects .</brief_summary>
	<brief_title>A Placebo-Controlled , Dose-Escalating Study Examine Safety Tolerability Single Intravenous Doses CF-301 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Bacteremia</mesh_term>
	<criteria>1 . Be healthy male race ethnicity , least 18 year age 55 year age , inclusively , OR 2 . Be healthy female race ethnicity nonchildbearing potential 18 55 year age , inclusive . OR 3 . Be healthy nonpregnant , nonlactating female race ethnicity childbearing potential 18 55 year age , 4 . Contraception use least 60 day prior Screening visit , 5 . Have body mass index ( BMI ) 18.5 32 kg/m2 , inclusive 6 . Have significant disease opinion Investigator medical history clinically significant finding physical examination clinical laboratory evaluation . 1 . Any disease condition opinion Investigator might compromise cardiovascular , hematologic , renal , hepatic , pulmonary ( include chronic asthma ) , endocrine ( eg , diabetes ) , central nervous , gastrointestinal ( include ulcer ) system . 2 . The presence clinically significant laboratory value normal range . − Subjects aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , gammaglutamyltransferase ( GGT ) , alkaline phosphatase , bilirubin , blood urea nitrogen ( BUN ) , creatinine , prothrombin time ( PT ) , activate partial thromboplastin time ( aPTT ) &gt; 5 % upper limit normal , hemoglobin hematocrit level &lt; 5 % low limit normal may enrol . 3 . A history alcoholism drug addiction , illicit drug use within past 2 year , positive result urine screen substance abuse . 4 . Has smoke within 28 day prior receive study drug positive urine test cotinine . 5 . A history serious mental illness . 6 . A history difficulty donate blood inadequate venous access . 7 . The donation blood plasma within 28 day prior receive study drug . 8 . A positive hepatitis screen test hepatitis B surface antigen ( HBsAg ) antibody hepatitis C virus ( HCVAb ) . 9 . A positive test result human immunodeficiency virus ( HIV ) antibody enzyme immunoassay , confirm Western blot . 10 . Use investigational drug product , participation drug study within period 28 day prior receive study drug ( investigational drug elimination halflife great 10 day , extend 60 day ) . 11 . Use prescription overthecounter ( OTC ) drug therapy , include herbal , homeopathic , vitamin , mineral nutritional supplement , within 2 week prior receive study drug contraceptive woman childbearing potential allow study . − If subject take prescription drug therapy chronic disease , prescription stop order qualify study , subject enrol study . 12 . Use drug therapy ( ie , prescription drug , overthe counter product , herbal vitamin product ) know induce inhibit cytochrome P450 hepatic enzyme responsible drug metabolism within 28 day prior receive study drug study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>